Literature DB >> 8691927

Growth and adrenal suppression in asthmatic children treated with high-dose fluticasone propionate.

G Todd1, K Dunlop, J McNaboe, M F Ryan, D Carson, M D Shields.   

Abstract

BACKGROUND: Fluticasone propionate was introduced in 1993 in the UK as a potentially safer inhaled corticosteroid than those already in use. The efficacy and safety of fluticasone has been established at recommended doses of 200 micrograms/day, but not at higher doses that are often used.
METHODS: Growth retardation was observed in six severely asthmatic children after introduction of high-dose fluticasone propionate treatment (dry powder). Assessment of cortisol response was by insulin-induced hypoglycaemia in three cases, by short tetracosactrin test in two, and by low-dose tetracosactrin and 24-hour urinary cortisol/creatinine ratio in one.
FINDINGS: Six children with growth retardation noted after treatment with high-dose fluticasone propionate were found to have adrenal suppression. In one case the growth rate and cortisol response returned to normal 9 months after the fluticasone dose was reduced to 500 micrograms/day.
INTERPRETATION: When high doses of fluticasone propionate are used, growth may be retarded and adrenal suppression may occur.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8691927     DOI: 10.1016/s0140-6736(96)03339-9

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  23 in total

1.  Symptomatic adrenal insufficiency presenting with hypoglycaemia in children with asthma receiving high dose inhaled fluticasone propionate.

Authors:  A J Drake; R J Howells; J P H Shield; A Prendiville; P S Ward; E C Crowne
Journal:  BMJ       Date:  2002-05-04

Review 2.  Anti-leukotriene agents compared to inhaled corticosteroids in the management of recurrent and/or chronic asthma in adults and children.

Authors:  Bhupendrasinh F Chauhan; Francine M Ducharme
Journal:  Cochrane Database Syst Rev       Date:  2012-05-16

3.  High-dose inhaled fluticasone, adrenal crisis and a fatal accident inquiry.

Authors:  Geoffrey Todd
Journal:  Arch Dis Child       Date:  2007-04       Impact factor: 3.791

4.  Prescribed doses of inhaled steroids in Dutch children: too little or too much, for too short a time.

Authors:  Eric Schirm; Tjalling W de Vries; Hilde Tobi; Paul B van den Berg; Lolkje T W de Jong-van den Berg
Journal:  Br J Clin Pharmacol       Date:  2006-06-23       Impact factor: 4.335

5.  Suppression of HPA axis in adults taking inhaled corticosteroids.

Authors:  J R Greenfield; K Samaras
Journal:  Thorax       Date:  2006-03       Impact factor: 9.139

Review 6.  Asthma treatment and growth.

Authors:  N J Shaw; N C Fraser; P H Weller
Journal:  Arch Dis Child       Date:  1997-10       Impact factor: 3.791

7.  Update on childhood asthma.

Authors:  R Evans
Journal:  West J Med       Date:  1997-05

Review 8.  Inhaled fluticasone propionate. A pharmacoeconomic review of its use in the management of asthma.

Authors:  H M Lamb; C R Culy; D Faulds
Journal:  Pharmacoeconomics       Date:  2000-11       Impact factor: 4.981

Review 9.  Antiasthmatic drug delivery in children.

Authors:  Elizabeth Biggart; Andrew Bush
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

Review 10.  Safety of the newer inhaled corticosteroids in childhood asthma.

Authors:  Tabitha L Randell; Kim C Donaghue; Geoffrey R Ambler; Christopher T Cowell; Dominic A Fitzgerald; Peter P van Asperen
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.